Thrivent Financial for Lutherans
KDNY

Thrivent Financial for Lutherans’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Thrivent Financial for Lutherans’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-18,690
Closed -$256K – 2311
2020
Q1 		$256K Buy
+18,690
New +$221K ﹤0.01% 2045

Other funds holding KDNY

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Thrivent Financial for Lutherans's KDNY Position: Q2 2020 in Review

Thrivent Financial for Lutherans sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q2 2020, closing a stake of 18,690 shares — an estimated $256K sold.

Thrivent Financial for Lutherans first reported a position in KDNY in Q1 2020 and held it in 1 quarter. The position peaked at $256K in Q1 2020. 90 funds tracked by Wall St. Rank hold KDNY as of Q2 2020.

  • Thrivent Financial for Lutherans reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • Thrivent Financial for Lutherans sold 18,690 Chinook Therapeutics, Inc. Common Stock shares in Q2 2020, an estimated $256K.
  • Thrivent Financial for Lutherans first reported a position in Chinook Therapeutics, Inc. Common Stock in Q1 2020 and held it in 1 quarter.
  • Thrivent Financial for Lutherans's Chinook Therapeutics, Inc. Common Stock position peaked at $256K in Q1 2020.
  • 90 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q2 2020.

Based on Thrivent Financial for Lutherans's 13F filing for Q2 2020, filed 12 Aug 2020.